The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
Jin-Hyuk Choi, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Mi Sun Ahn, Young-Taek Oh, O kyu Noh, Se-Hyuk Kim, Tae Hoon Roh, Seung Soo Sheen
Korean J Intern Med. 2022;37(2):434-443. Published online 2022 Feb 16 DOI: https://doi.org/10.3904/kjim.2021.315
Citations to this article as recorded by 
Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: a multi-center retrospective analysis
Yaru Kong, Yunchuan Sun, Li Xiao, Hongling Lu, Rui Wang, Yongchao Yu, Jianxi Zhou, Jiaju Zhang, Yingnan Zhou
Frontiers in Oncology.2026;[Epub] CrossRef
Incidence and Radiological Spectrum of Interstitial Lung Disease in Patients With Lung Cancer Treated With Tyrosine Kinase Inhibitors: A Single-Center Observational Study
Supantha De, Prasanta R Mohapatra, Mahismita Patro, Sudipta Mohakud, Pritinanda Mishra, Sourin Bhuniya, Manoj Panigrahi, Shakti Bal, Mukund Sable, Aneri Parekh , Siddarth Singh, Nilava Banerjee
Cureus.2026;[Epub] CrossRef
Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis
Zihan Zeng, Simin Feng, Tinghua Gao, Chengye Chen, Jun Chen, Junliang Chen, Yingni Lian
Clinical Lung Cancer.2025; 26(6): e391. CrossRef
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
BMC Cancer.2024;[Epub] CrossRef